Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lademirsen - Regulus Therapeutics

Next Previous
Drug Profile

Lademirsen - Regulus Therapeutics

Alternative Names: Lademirsen sodium; RG 012; RG 456070; SAR 339375

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regulus Therapeutics; Sanofi
  • Class Antisense oligoribonucleotides; MicroRNAs; Urologics
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hereditary nephritis

Most Recent Events

  • 07 Apr 2023 Sanofi terminates its R & D agreement with Regulus Therapeutics for Lademirsen
  • 28 Jul 2022 Discontinued - Phase-II for Hereditary nephritis in USA, Spain, Germany, France, China, Canada, Australia, United Kingdom (SC) as of July 2022
  • 28 Feb 2022 Regulus Therapeutics completes enrolment in the phase II HERA trial in Alport syndrome
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top